The ABCs (antibody, B cells, and carbohydrate epitopes) of cholera immunity: Considerations for an improved vaccine

Microbiology and Immunology

Volumn 50, Issue 12, 2006, Pages 899-927

  Provenzano, Daniele ^a   Kováč, Pavol ^b   Wade, William F ^c  

^a UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Antibody; B cells; Cholera vaccine; Immunity; LPS

Indexed keywords

CARBOHYDRATE; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CYTOKINE; EPITOPE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOPOLYSACCHARIDE ANTIBODY; LIPOPOLYSACCHARIDE CHOLERA VACCINE; TOLL LIKE RECEPTOR;

ACCESSORY CELL; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; B LYMPHOCYTE; CELL INFILTRATION; CHOLERA; CLINICAL TRIAL; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; INFECTION RISK; INNATE IMMUNITY; LEUKOCYTE; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; RURAL POPULATION; SEROTYPING; SINGLE DRUG DOSE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIBRIO CHOLERAE;

VIBRIO CHOLERAE;

EID: 33845757220     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03866.x     Document Type: Review

References (258)

1. Adams, L.B., Henk, M.C., and Siebeling, R.J. 1998. Detection of Vibrio cholerae with monoclonal antibodies specific for serovar O1 lipopolysaccharide. J. Clin. Microbiol. 26: 1801-1809.
2. Ahmed, A., Bhattacharjee, A.K., and Mosley, W.H. 1970. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. J. Immunol. 105: 431-441.
3. Albert, M.J., Qadri, F., Wahed, M.A., Ahmed, T., Rahman, A.S., Ahmed, F., Bhuiyan, N.A., Zaman, K., Baqui, A.H., Clemens, J.D., and Black, R.E. 2003. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J. Infect. Dis. 187: 909-913.
4. Ali, M., Emch, M., von Seidlein, L., Yunus, M., Sack, D.A., Rao, M., Holmgren, J., and Clemens, J.D. 2005. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366: 44-49.
5. Alugupalli, K.R., Leong, J.M., Woodland, R.T., Muramatsu, M., Honjo, T., and Gerstein, R.M. 2004. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 21: 379-390.
6. Anderson, S.J., and Lawton, A.R. 1987. LPS augments human B-cell differentiation by direct stimulation of PWM-responsive B cells. Clin. Immunol. Immunopathol. 44: 259-271.
7. Ansel, K.M., Harris, R.B., and Cyster, J.G. 2002. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 16: 67-76.
8. Apter, F.M., Michetti, P., Winner, L.S., 3rd, Mack, J.A., Mekalanos, J.J., and Neutra, M.R. 1993. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect. Immun. 61: 5279-5285.
9. Attanavanich, K., and Kearney, J.F. 2004. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol. 172: 803-811.
10. Azurin, J.C., Cruz, A., Pesigan, T.P., Alvero, M., Camena, T., Suplido, R., Ledesma, L., and Gomez, C.Z. 1967. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull. World Health Organ. 37: 703-727.
11. Begue, R.E., Castellares, G., Cabezas, C., Sanchez, J.L., Meza, R., Watts, D.M., and Taylor, D.N. 1995. Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit. Infect. Immun. 63: 3726-3728.
12. Benenson, A.S., Joseph, P.R., and Oseasohn, R.O. 1968. Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies. Bull. World Health Organ. 38: 347-357.
13. Benenson, A.S., Mosley, W.H., Fahimuddin, M., and Oseasohn, R.O. 1968. Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field. Bull. World Health Organ. 38: 359-372.
14. Berland, R., and Wortis, H.H. 2002. Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 20: 253-300.
15. Bernasconi, N.L., Onai, N., and Lanzavecchia, A. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504.
16. Bernatowska, E., Jose, P., Davies, H., Stephenson, M., and Webster, D. 1989. Interaction of campylobacter species with antibody, complement and phagocytes. Gut 30: 906-911.
17. Bhadra, R.K., Dasgupta, U., and Das, J. 1994. Cholera vaccine: developmental strategies and problems. Indian J. Biochem. Biophys. 31: 441-448.
18. Bhaskaran, K., and Gorrill, R.H. 1957. A study of antigenic variation in Vibrio cholerae. J. Gen. Microbiol. 16: 721-729.
19. Bhattacharya, M.K., Dutta, D., Deb, A., Garg, P., Chakraborty, S., Mukhopadhyay, A.K., Bhattacharya, S.K., and Moitra, A. 1989. Acute secretory traveller's diarrhoea caused by Vibrio cholerae which does not belong to the O1 or O139 serogroup. Natl. Med. J. India 11: 248-249.
20. Bishop, G.A., and Hostager, B.S. 2003. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 14: 297-309.
21. Black, R.E., Levine, M.M., Clements, M.L., Young, C.R., Svennerholm, A.M., and Holmgren, J. 1987. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 55: 1116-1120.
22. Blanchard, T.G., Czinn, S.J., and Nedrud, J.G. 1999. Host response and vaccine development to Helicobacter pylori infection. Curr. Top. Microbiol. Immunol. 241: 181-213.
23. Bollinger, R.R., Everett, M.L., Palestrant, D., Love, S.D., Lin, S.S., and Parker, W. 2003. Human secretory immunoglobulin A may contribute to biofilm formation in the gut. Immunology 109: 580-587.
24. Bos, N.A., Meeuwsen, C.G., Wostmann, B.S., Pleasants, J.R., and Benner, R. 1988. The influence of exogenous antigenic stimulation on the specificity repertoire of background immunoglobulin-secreting cells of different isotypes. Cell. Immunol. 112: 371-380.
25. Bos, N.A., Bun, J.C., Popma, S.H., Cebra, E.R., Deenen, G.J., van der Cammen, M.J., Kroese, F.G., and Cebra, J.J. 1996. Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria. Infect. Immun. 64: 616-623.
26. Bourke, E., Bosisio, D., Golay, J., Polentarutti, N., and Mantovani, A. 2003. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102: 956-963.
27. Boursier, L., Dunn-Walters, D.K., and Spencer, J. 1999. Characteristics of IgVH genes used by human intestinal plasma cells from childhood. Immunology 97: 558-564.
28. Boursier, L., Gordon, J.N., Thiagamoorthy, S., Edgeworth, J.D., and Spencer, J. 2005. Human intestinal IgA response is generated in the organized gut-associated lymphoid tissue but not in the lamina propria. Gastroenterology 128: 1879-1889.
29. Boutonnier, A., Villeneuve, S., Nato, F., Dassy, B., and Fournier, J.M. 2001. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect. Immun. 69: 3488-3493.
30. Boutonnier, A., Dassy, B., Dumenil, R., Guenole, A., Ratsitorahina, M., Migliani, R., and Fournier, J.M. 2003. A simple and convenient microtiter plate assay for the detection of bactericidal antibodies to Vibrio cholerae O1 and Vibrio cholerae O139. J. Microbiol. Meth. 55: 745-753.
31. Bouvet, J.P., and Fischetti, V.A. 1999. Diversity of antibody-mediated immunity at the mucosal barrier. Infect. Immun. 67: 2687-2691.
32. Brandtzaeg, P. 2003. Role of secretory antibodies in the defense against infections. Int. J. Med. Microbiol. 293: 3-15.
33. Brisslert, M., Bokarewa, M., Larsson, P., Wing, K., Collins, L.V., and Tarkowski, A. 2006. Phenotypic and functional characterization of human CD25 B cells. Immunology 117: 548-557.
34. Butler, T. 2001. New developments in the understanding of cholera. Curr. Gastroenterol. Rep. 3: 315-321.
35. Calain, P., Chaine, J.P., Johnson, E., Hawley, M.L., O'Leary, M.J., Oshitani, H., and Chaignat, C.L. 2004. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22: 2444-2451.
36. Caroff, M., Karibian, D., Cavaillon, J.M., and Haeffner-Cavaillon, N. 2002. Structural and functional analyses of bacterial lipopolysaccharides. Microbes Infect. 4: 915-926.
37. Carroll, M.C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5: 981-986.
38. Carroll, M.C., and Prodeus, A.P. 1998. Linkages of innate and adaptive immunity. Curr. Opin. Immunol. 10: 36-40.
39. Chaicumpa, W., and Rowley, D. 1973. Mechanisms of antibacterial immunity against Vibrio cholerae in the intestinal tracts of baby mice. J. Infect. Dis. 128: 56-62.
40. Chatterjee, S.N., and Chaudhuri, K. 2003. Lipopolysaccharides of Vibrio cholerae. I. Physical and chemical characterization. Biochim. Biophys. Acta 1639: 65-79.
41. Chelvarajan, R.L., Collins, S.M., Doubinskaia, I.E., Goes, S., Van Willigen, J., Flanagan, D., De Villiers, W.J., Bryson, J.S., and Bondada, S. 2004. Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens. J. Leukoc. Biol. 75: 982-994.
42. Chelvarajan, R.L., Collins, S.M., Van Willigen, J.M., and Bondada, S. 2005. The unresponsiveness of aged mice to polysaccharide antigens is a result of a defect in macrophage function. J. Leukoc. Biol. 77: 503-512.
43. Chernyak, A., Kondo, S., Wade, T.K., Meeks, M.D., Alzari, P.M., Fournier, J.M., Taylor, R.K., Kovac, P., and Wade, W.F. 2002. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J. Infect. Dis. 185: 950-962.
44. Chiang, S.L., and Mekalanos, J.J. 1999. rfb mutations in Vibrio cholerae do not affect surface production of toxin-coregulated pili but still inhibit intestinal colonization. Infect. Immun. 67: 976-980.
45. Chongsa-nguan, M., Chaicumpa, W., Kalambaheti, T., Soejoedi, H., Luxananil, P., Swasdikosa, S., Thanasiri, P., and Mayurasakorn, S. 1986. Vibriocidal antibody and antibodies to Vibrio cholerae lipopolysaccharide, cell-bound haemagglutinin and toxin in Thai population. Asian J. Trop. Med. Public Health 17: 558-566.
46. Clemens, J.D., Harris, J.R., Sack, D.A., Chakraborty, J., Ahmed, F., Stanton, B.F., Khan, M.U., Kay, B.A., Huda, N., Khan, M.R., et al. 1988. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 158: 60-69.
47. Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Khan, M.R., Huda, S., Ahmed, F., Gomes, J., Rao, M.R., and Svennerholm, A.M. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis. 159: 770-773.
48. Clemens, J.D., Sack, D.A., Harris, J.R., Khan, M.R., Chakraborty, J., Chowdhury, S., Rao, M.R., van Loon, F.P., Stanton, B.F., Yunus, M., et al. 1990. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am. J. Epidemiol. 131: 400-411.
49. Clemens, J.D., Sack, D.A., Chakraborty, J., Rao, M.R., Ahmed, F., Harris, J.R., van Loon, F., Khan, M.R., Yunis, M., Huda, S., et al. 1990. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 8: 469-472.
50. Clemens, J.D., van Loon, F., Sack, D.A., Chakraborty, J., Rao, M.R., Ahmed, F., Harris, J.R., Khan, M.R., Yunus, M., Huda, S, et al. 1991. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163: 1235-1242.
51. Cohen, D., Ashkenazi, S., Green, M., Lerman, Y., Slepon, R., Robin, G., Orr, N., Taylor, D.N., Sadoff, J.C., Chu, C., Shiloach, J., Schneerson, R., and Robbins, J.B. 1996. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect. Immun. 64: 4074-4077.
52. Colle, J.H., Motta, I., and Truffa-Bachi, P. 1983. Generation of immune memory by haptenated derivatives of thymus-independent antigens in C57Bl/6 mice. I. The differentiation of memory B lymphocytes into antibody-secreting cells depends on the nature of the thymus-independent carrier used for memory induction and/or reevaluation. Cell. Immunol. 75: 52-62.
53. Colle, J.-H., Truffa-Bachi, P., and Freitas, A.A. 1988. Secondary antibody responses to thymus-independent antigens. Decline and life-span of memory. Eur. J. Immunol. 18: 1307-1314.
54. Cooper, P.J., Chico, M., Sandoval, C., Espinel, I., Guevara, A., Levine, M.M., Griffin, G.E., and Nutman, T.B. 2001. Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect. Immun. 69: 1574-1580.
55. Corbel, C., and Melchers, F. 1983. Requirement for macrophages or for macrophage- or T cell-derived factors in the mitogenic stimulation of murine B lymphocytes by lipopolysaccharides. Eur. J. Immunol. 13: 528-533.
56. Corley, R.B., Morehouse, E.M., and Ferguson, A.R. 2005. IgM accelerates affinity maturation. Scand. J. Immunol. 62 (Suppl 1): 55-61
57. Cox, A.D., and Perry, M.B. 1996. Structural analysis of the O-antigen-core region of the lipopolysaccharide from Vibrio cholerae O139. Carbohydr. Res. 290: 59-65.
58. Croft, N.M., and Hodges, M. 2005. IgM: mucosal response in acute diarrhoeal disease of infants. Scand. J. Gastroenterol. 40: 965-971.
59. Dalsgaard, A., Forslund, A., Bodhidatta, L., Serichantalergs, O., Pitarangsi, C., Pang, L., Shimada, T., and Echeverria, P. 1999. A high proportion of Vibrio cholerae strains isolated from children with diarrhoea in Bangkok, Thailand are multiple antibiotic resistant and belong to heterogenous non-O1, non-O139 O-serotypes. Epidemiol. Infect. 122: 217-226.
60. Dasari, P., Nicholson, I.C., Hodge, G., Dandie, G.W., and Zola, H. 2005. Expression of toll-like receptors on B lymphocytes. Cell. Immunol. 236: 140-145.
61. Devi, S.J., Hayat, U., Powell, J.L., and Morris, J.G., Jr. 1996. Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharidetetanus toxoid conjugate vaccines of Vibrio vulnificus. Infect. Immun. 64: 2220-2224.
62. + B-cell. Int. J. Biochem. Cell Biol. 36: 2105-2111.
63. Dono, M., Zupo, S., Leanza, N., Melioli, G., Fogli, M., Melagrana, A., Chiorazzi, N., and Ferrarini, M. 2000. Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J. Immunol. 164: 5596-5604.
64. Ehara, M., Ichinose, Y., Iwami, M., Utsunomiya, A., Shimodori, S., Kangethe, S.K., Neves, B.C., Supawat, K., and Nakamura, S. 1993. Immunogenicity of Vibrio cholerae O1 fimbriae in animal and human cholera. Microbiol. Immunol. 37: 679-688.
65. Fagarasan, S., Shinkura, R., Kamata, T., Nogaki, F., Ikuta, K., and Honjo, T. 2000. Mechanism of B1 cell differentiation and migration in GALT. Curr. Top. Microbiol. Immunol. 252: 221-229.
66. Falero, G., Rodriguez, B.L., Rodriguez, I., Campos, J., Ledon, T., Valle, E., Silva, Y., Marrero, K., Suzarte, E., Valmaseda, T., Moreno, A., and Fando, R. 2003. Production and characterization of monoclonal antibodies to E1 Tor toxin co-regulated pilus of Vibrio cholerae. Hybrid Hybridomics. 22: 315-320.
67. Falklind-Jerkerus, S., Felici, F., Cavalieri, C., Lo Passo, C., Garufi, G., Pernice, I., Islam, M.M., Qadri, F., and Weintraub, A. 2005. Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response. Microbes Infect. 7: 1453-1460.
68. Farstad, I.N., Carlsen, H., Morton, H.C., and Brandtzaeg, P. 2000. Immunoglobulin A cell distribution in the human small intestine: phenotypic and functional characteristics. Immunology 101: 354-363.
69. Faruque, S.M., Islam, M.J., Ahmad, Q.S., Faruque, A.S., Sack, D.A., Nair, G.B., and Mekalanos, J.J. 2005. Self-limiting nature of seasonal cholera epidemics: role of host-mediated amplification of phage. Proc. Natl. Acad. Sci. U.S.A. 102: 6119-6124.
70. Feeley, J. C. 1970. Cholera vaccines. Public Health Pap. 40: 87-93.
71. Finkelstein, R.A. 1995. Why do we not yet have a suitable vaccine against cholera? Adv. Exp. Med. Biol. 371B: 1633-1640.
72. Fischer, M., and Kuppers, R. 1998. Human IgA- and IgM-secreting intestinal plasma cells carry heavily mutated VH region genes. Eur. J. Immunol. 28: 2971-2977.
73. Fresh, J.W., Versage, P.M., and Reyes, V. 1964. Intestinal morphology in human and experimental cholera. Arch. Pathol. 77: 529-537.
74. Fries, L.F., Montemarano, A.D., Mallett, C.P., Taylor, D.N., Hale, T.L., and Lowell, G.H. 2001. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69: 4545-4553.
75. Friman, V., Quiding, M., Czerkinsky, C., Nordstrom, I., Larsson, L., Ericson, D., Bjorkander, J., Theman, K., Kilander, A., Holmgren, J., et al. 1994. Intestinal and circulating antibody-forming cells in IgA-deficient individuals after oral cholera vaccination. Clin. Exp. Immunol. 95: 222-226.
76. Fuerst, J.A., and Perry, J.W. 1988. Demonstration of lipopolysaccharide on sheathed flagella of Vibrio cholerae O:1 by protein A-gold immunoelectron microscopy. J. Bacteriol. 170: 1488-1494.
77. Ganguly, N.K., and Kaur, T. 1996. Mechanism of action of cholera toxin and other toxins. Indian J. Med. Res. 104: 28-37.
78. Ganguly, R., Clem, L.W., Bencic, Z., Sinha, R., Sakazaki, R., and Waldman, R.H. 1975. Antibody response in the intestinal secretions of volunteers immunized with various cholera vaccines. Bull. World Health Organ. 52: 323-330.
79. Gateff, C., Dewitt, W.E., Lemarinier, G., Bradley, M., and Labusquiere, R. 1997. Vibriocidal antibodies after anticholera vaccination with a jet injector without a needle. Med. Trop. 31: 723-730.
80. Getahun, A., and Heyman, B. 2006. How antibodies act as natural adjuvants. Immunol. Lett. 104: 38-45.
81. Ghosh, S., and Campbell, A.M. 1988. Unusual cross-reactions among monoclonal antibodies to bacterial antigens: idiotypic and competitive binding analysis. FEMS Microbiol. Immunol. 1: 3-8.
82. Glass, R.I., Becker, S., Huq, M.I., Stoll, B.J., Khan, M.U., Merson, M.H., Lee, J.V., and Black, R, E. 1982. Endemic cholera in rural Bangladesh, 1966-1980. Am. J. Epidemiol. 116: 959-970.
83. Glass, R.I., Svennerholm, A.M., Stoll, B.J., Khan, M.R., Hossain, K.M., Huq, M.I., and Holmgren, J. 1983. Protection against cholera in breast-fed children by antibodies in breast milk. N. Engl. J. Med. 308: 1389-1392.
84. Glass, R.I., Holmgren, J., Haley, C.E., Khan, M.R., Svennerholm, A.M., Stoll, B.J., Belayet Hossain, K.M., Black, R.E., Yunus, M., and Barua, D. 1985. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 121: 791-796.
85. Gonzalez, L., Asensio, J.L., Ariosa-Alvarez, A., Verez-Bencomo, V., and Jimenez-Barbero, J. 1999. Solution conformation and dynamics of the trisaccharide fragments of the O-antigen of Vibrio cholerae O1, serotypes Inaba and Ogawa. Carbohydr. Res. 321: 88-95.
86. Gotuzzo, E., Butron, B., Seas, C., Penny, M., Ruiz, R., Losonsky, G., Lanata, C.F., Wasserman, S.S., Salazar, E., Kaper, J.B., Cryz, S., and Levine, M.M. 1993. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61: 3994-3997.
87. Gupta, R.K., Szu, S.C., Finkelstein, R.A., and Robbins, J.B. 1992. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60: 3201-3208.
88. Gupta, R.K., Taylor, D.N., Bryla, D.A., Robbins, R.B., and Szu, S.C. 1998. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect. Immun. 66: 3095-3099.
89. Gustafsson, B. 1984. Monoclonal antibody-based enzyme-linked immunosorbent assays for identification and serotyping of Vibrio cholerae O1. J. Clin. Microbiol. 20: 1180-1185.
90. Gustafsson, B., and Holme, T. 1983. Monoclonal antibodies against group- and type-specific lipopolysaccharide antigens of Vibrio cholerae O:1. J. Clin. Microbiol. 18: 480-485.
91. Gustafsson, B., and Holme, T. 1985. Rapid detection of Vibrio cholerae O:1 by motility inhibition and immunofluorescence with monoclonal antibodies. Eur. J. Clin. Microbiol. 4: 291-294.
92. Gustafsson, B., Rosen, A., and Holme, T. 1982. Monoclonal antibodies against Vibrio cholerae lipopolysaccharide. Infect. Immun. 38: 449-454.
93. Haas, K.M., Poe, J.C., Steeber, D.A., and Tedder, T.F. 2005. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23: 7-18.
94. Hallander, H.O., Paniagua, M., Espinoza, F., Askelof, P., Corrales, E., Ringman, M., and Storsaeter, J. 2002. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 21: 138-145.
95. Halstensen, T.S., Mollnes, T.E., Garred, P., Fausa, O., and Brandtzaeg, P. 1992. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 33: 902-908.
96. Harris, J.B., Khan, A.I., LaRocque, R.C., Dorer, D.J., Chowdhury, F., Faruque, A.S., Sack, D.A., Ryan, E.T., Qadri, F., and Calderwood, S.B. 2005. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect. Immun. 73: 7422-7427.
97. Haury, M., Sundblad, A., Grandien, A., Barreau, C., Coutinho, A., and Nobrega, A. 1997. The repertoire of serum IgM in normal mice is largely independent of external antigenic contact. Eur. J. Immunol. 27: 1557-1563.
98. Hayakawa, K., Asano, M., Shinton, S.A., Gui, M., Allman, D., Stewart, C.L., Silver, J., and Hardy, R.R. 1999. Positive selection of natural autoreactive B cells. Science 285: 113-116.
99. Herrington, D.A., Hall, R.H., Losonsky, G., Mekalanos, J.J., Taylor, R.K., and Levine, M.M. 1988. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J. Exp. Med. 168: 1487-1492.
100. Hisatsune, K., Kondo, S., Isshiki, Y., Iguchi, T., and Haishima, Y. 1993. Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. Biochem. Biophys. Res. Commun. 190: 302-307.
101. Hisatsune, K., Kondo, S., Iguchi, T., Ito, T., and Hiramatsu, K. 1996. Lipopolysaccharides of Escherichia coli K12 strains that express cloned genes for the Ogawa and Inaba antigens of Vibrio cholerae O1: identification of O-antigenic factors. Microbiol. Immunol. 40: 621-626.
102. Holmgren, J., and Svennerholm, A.M. 1992. Bacterial enteric infections and vaccine development. Gastroenterol. Clin. North Am. 21: 283-302.
103. Hoque, S.S., Ghosh, S., and Poxton, I.R. 2000. Differences in intestinal humoral immunity between healthy volunteers from UK and Bangladesh. Eur. J. Gastroenterol. Hepatol. 12: 1185-1193.
104. Iredell, J.R., and Manning, P.A. 1994. Biotype-specific tcpA genes in Vibrio cholerae. FEMS Microbiol. Lett. 121: 47-54.
105. Isshiki, Y., Haishima, Y., Kondo, S., and Hisatsune, K. 1992. Serological cross-reaction between intact and chemically-modified lipopolysaccharides of O1 Vibrio cholerae Inaba andnon-O1V. cholerae bio-serogroup Hakata. Microbiol. Immunol. 36: 1201-1205.
106. Jacobs, D.M. 1975. Structural and genetic basis of the in vivo immune response to TNP-LPS. J. Immunol. 115: 988-992.
107. Jertborn, M., Svennerholm, A.M., and Holmgren, J. 1996. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 14: 1459-1465.
108. Johansen, F.E., Pekna, M., Norderhaug, I.N., Haneberg, B., Hietala, M.A., Krajci, P., Betsholtz, C., and Brandtzaeg, P. 1999. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J. Exp. Med. 190: 915-922.
109. Jonson, G., Osek, J., Svennerholm, A.M., and Holmgren, J. 1996. Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development. Infect. Immun. 64: 3778-3785.
110. Joo, I. 1973. Occurrence of "natural" vibriocidal antibodies in the population of a non-endemic area. Boll. Ist. Sieroter. Milan. 52: 224-229.
111. Kabir, S. 1987. Preparation and immunogenicity of a bivalent cell-surface protein-polysaccharide conjugate of Vibrio cholerae. J. Med. Microbiol. 23: 9-18.
112. Kanoh, T., Mizumoto, T., Yasuda, N., Koya, M., Ohno, Y., Uchino, H., Yoshimura, K., Ohkubo, Y., and Yamaguchi, H. 1986. Selective IgA deficiency in Japanese blood donors: frequency and statistical analysis. Vox. Sang. 50: 81-86.
113. Kantor, A.B., and Herzenberg, L.A. 1993. Origin of murine B cell lineages. Annu. Rev. Immunol. 11: 501-538.
114. Kately, J.R., Patel, C.B., and Friedman, H. 1975. Involvement of T- and B-lymphocytes in the immune response to the protein exotoxin and the lipopolysaccharide antigens of Vibrio cholerae. Ann. N.Y. Acad. Sci. 249: 404-412.
115. Kearney, J.F. 2003. Development and function of B cell subsets, p. 156-160. In Paul, W.E. (ed), Fundametnal Immunology, Lippincott, Williams and Wilkins, Philadelphia.
116. Kearney, J.F. 2005. Innate-like B cells. Springer Semin. Immunopathol. 26: 377-383.
117. Kelly, D.F., Moxon, E.R., and Pollard, A.J. 2004. Haemophilus influenzae type b conjugate vaccines. Immunology 113: 163-174.
118. Kelly, D.F., Pollard, A.J., and Moxon, E.R. 2005. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 294: 3019-3023.
119. Kenner, J.R., Coster, T.S., Taylor, D.N., Trofa, A.F., Barrera-Oro, M., Hyman, T., Adams, J.M., Beattie, D.T., Killeen, K.P., Spriggs, D.R., et al. 1995. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis. 172: 1126-1129.
120. Keren, D.F., McDonald, R.A., and Carey, J.L. 1988. Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri. Infect. Immun. 56: 910-915.
121. Kirimanjeswara, G.S., Mann, P.B., Pilione, M., Kennett, M.J., and Harvill, E.T. 2005. The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J. Immunol. 175: 7504-7511.
122. Kirn, T.J., Lafferty, M.J., Sandoe, C.M., and Taylor, R.K. 2000. Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by Vibrio cholerae. Mol. Microbiol. 35: 896-910.
123. Kirn, T.J., and Taylor, R.K. 2005. TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect. Immun. 73: 4461-4470.
124. Klose, K.E. 2000. The suckling mouse model of cholera. Trends Microbiol. 8: 189-191.
125. Koch, G., Lok, B.D., and Benner, R. 1982. Antibody formation in mouse bone marrow during secondary type responses to various thymus-independent antigens. Immunobiology 163: 484-496.
126. Koelle, K., Rodo, X., Pascual, M., Yunus, M., and Mostafa, G. 2005. Refractory periods and climate forcing in cholera dynamics. Nature 436: 696-700.
127. Kotloff, K.L., Wasserman, S.S., O'Donnell, S., Losonsky, G.A., Cryz, S.J., and Levine, M.M. 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect. Immun. 60: 4430-4432.
128. Kraal, G. 1992. Cells in the marginal zone of the spleen. Int. Rev. Cytol. 132: 31-74.
129. Kroese, F.G., Butcher, E.C., Stall, A.M., Lalor, P.A., Adams, S., and Herzenberg, L.A. 1989. Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int. Immunol. 1: 75-84.
130. Kruschinski, C., Zidan, M., Debertin, A.S., von Horsten, S., and Pabst, R. 2004. Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum. Pathol. 35: 113-121.
131. Lagos, R., Avendano, A., Prado, V., Horwitz, I., Wasserman, S., Losonsky, G., Cryz, S., Jr., Kaper, J.B., and Levine, M.M. 1995. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63: 707-719.
132. Lagos, R., Fasano, A., Wasserman, S.S., Prado, V., San Martin, O., Abrego, P., Losonsky, G.A., Alegria, S., and Levine, M.M. 1999. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180: 1709-1712.
133. Lagos, R., San Martin, O., Wasserman, S.S., Prado, V., Losonsky, G.A., Bustamante, C., and Levine, M.M. 1999. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr. Infect. Dis. J. 18: 624-630.
134. Lausen, B.F., Hougs, L., Schejbel, L., Heilmann, C., and Barington, T. 2004. Human memory B cells transferred by allogenic bone marrow transplantation contribute significantly to the antibody repertoire of the recipient. J. Immunol. 172: 3305-3318.
135. Lee, C.J., Lee, L.H., and Frasch, C.E. 2003. Protective immunity of pneumococcal glycoconjugates. Crit. Rev. Microbiol. 29: 333-349.
136. Lee, Y., Haas, K.M., Gor, D.O., Ding, X., Karp, D.R., Greenspan, N.S., Poe, J.C., and Tedder, T.F. 2005. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J. Immunol. 175: 8011-8023.
137. Leelawongtawon, R., Somroop, S., Chaisri, U., Tongtawe, P., Chongsa-nguan, M., Kalambaheti, T., Tapchaisri, P., Pichyangkul, S., Sakolvaree, Y., Kurazono, H., Hayashi, H., and Chaicumpa, W. 2003. CpG DNA, liposome and refined antigen oral cholera vaccine. Asian Pac. J. Aller. Immunol. 21: 231-239.
138. Levine, M.M. 1997. Oral vaccines against cholera: lessons from Vietnam and elsewhere. Lancet 349: 220-223.
139. Levine, M.M., Black, R.E., Clements, M.L., Cisneros, L., Nalin, D.R., and Young, C.R. 1981. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143: 818-820.
140. Levine, M.M., and Pierce, N.F. 1992. Immunity and vaccine development, p. 285-327. In Barua, D., and Greenough, W.B., III (eds), Plenum Press, New York.
141. Liao, X., Poirot, E., Chang, A.H., Zhang, X., Zhang, J., Nato, F., Fournier, J.M., Kovac, P., and Glaudemans, C.P. 2002. The binding of synthetic analogs of the upstream, terminal residue of the O-polysaccharides (O-PS) of Vibrio cholerae O:1 serotypes Ogawa and Inaba to two murine monoclonal antibodies (MAbs) specific for the Ogawa lipopolysaccharide (LPS). Carbohydr. Res. 337: 2437-2442.
142. Lopes-Carvalho, T., and Kearney, J.F. 2004. Development and selection of marginal zone B cells. Immunol. Rev. 197: 192-205.
143. Lorenz, R.G., and Newberry, R.D. 2004. Isolated lymphoid follicles can function as sites for induction of mucosal immune responses. Ann. N.Y. Acad. Sci. 1029: 44-57.
144. Losonsky, G.A., Yunyongying, J., Lim, V., Reymann, M., Lim, Y.L., Wasserman, S.S., and Levine, M.M. 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64: 10-15.
145. Losonsky, G.A., Tacket, C.O., Wasserman, S.S., Kaper, J.B., and Levine, M.M. 1993. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun. 61: 729-733.
146. Lucas, M.E., Deen, J.L., von Seidlein, L., Wang, X.Y., Ampuero, J., Puri, M., Ali, M., Ansaruzzaman, M., Amos, J., Macuamule, A., Cavailler, P., Guerin, P.J., Mahoudeau, C., Kahozi-Sangwa, P., Chaignat, C.L., Barreto, A., Songane, F.F., and Clemens, J.D. 2005. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med. 352: 757-767.
147. Lycke, N., Erlandsson, L., Ekman, L., Schon, K., and Leanderson, T. 1999. Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J. Immunol. 163: 913-919.
148. Lyubchenko, T., dal Porto, J., Cambier, J.C., and Holers, V.M. 2005. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J. Immunol. 174: 3264-3272.
149. MacLennan, I.C. 1994. Germinal centers. Annu. Rev. Immunol. 12: 117-139.
150. Makala, L.H., Suzuki, N., and Nagasawa, H. 2002-2003. Peyer's patches: organized lymphoid structures for the induction of mucosal immune responses in the intestine. Pathobiology 70: 55-68.
151. Manning, P.A., Stroeher, U.H., and Morona, R. 1994.. Molecular basis for O-antigen biosynthesis in Vibrio cholerae O1: Ogawa-Inaba switching, p. 77-94. In Wachsmuth, I.K., Blake, P.A., and Olsvik, O. (eds), Vibrio cholerae and cholera: moelcular to global perspectives.
152. Manz, R.A., Arce, S., Cassese, G., Hauser, A.E., Hiepe, F., and Radbruch, A. 2002. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol. 14: 517-521.
153. Martin, F., and Kearney, J.F. 2000. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory." Immunol. Rev. 175: 70-79.
154. Martin, F., Oliver, A.M., and Kearney, J.F. 2001. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14: 617-629.
155. Maruyama, M., Lam, K.P., and Rajewsky, K. 2000. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407: 636-642.
156. Mathan, M.M., Chandy, G., and Mathan, V.I. 1995. Ultrastructural changes in the upper small intestinal mucosa in patients with cholera. Gastroenterology 109: 422-430.
157. Mbawuike, I.N., Pacheco, S., Acuna, C.L., Switzer, K.C., Zhang, Y., and Harriman, G.R. 1999. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J. Immunol. 162: 2530-2537.
158. McBean, A.M., Agle, A.N., Compaore, P., Foster, S.O., and McCormack, W.M. 1972. Comparison of intradermal and subcutaneous routes of cholera vaccine administration. Lancet 1: 527-529.
159. Meeks, M.D., Saksena, R., Ma, X., Wade, T.K., Taylor, R.K., Kovac, P., and Wade, W.F. 2004. Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect. Immun. 72: 4090-4101.
160. Migasena, S., Desakorn, V., Suntharasamai, P., Pitisuttitham, P., Prayurahong, B., Supanaranond, W., and Black, R.E. 1989. Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect. Immun. 57: 117-120.
161. Mosley, W.H., Benenson, A.S., and Barui, R. 1968. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the immunized and control population of a cholera-vaccine fieldtrial area and the relation of antibody titre to cholera case rate. Bull. World Health Organ. 38: 335-346.
162. Mosley, W.H., Ahmad, S., Beneson, A.S., and Ahmed, A. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull. World Health Organ. 38: 777-785.
163. Mosley, W.H., Woodward, W.E., Aziz, K.M., Rahman, A.S., Chowdhury, A.K., Ahmed, A., and Feeley, J.C. 1970. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J. Infect. Dis. 121: 1-9.
164. Mosley, W.H., Aziz, K.M., Rahman, A.S., Chowdhury, A.K., and Ahmed, A. 1973. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh - three years of observation. Bull. World Health Organ. 49: 381-387.
165. Motta, I., Portnoi, D., and Truff-Bachi, P. 1981. Induction and differentiation of B memory cells by a thymus-independent antigen, trinitrophenylated lipopolysaccharide. Cell. Immunol. 57: 327-338.
166. Mrsny, R.J., Gewirtz, A.T., Siccardi, D., Savidge, T., Hurley, B.P., Madara. J.L., and McCormick, B.A. 2004. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc. Natl. Acad. Sci. U.S.A. 101: 7421-7426.
167. Mukhopadhyay, S., Nandi, B., and Ghose, A.C. 2000. Antibodies (IgG) to lipopolysaccharide of Vibrio cholerae O1 mediate protection through inhibition of intestinal adherence and colonisation in a mouse model. FEMS Microbiol. Lett. 185: 29-35.
168. Murakami, M., Tsubata, T., Shinkura, R., Nisitani, S., Okamoto, M., Yoshioka, H., Usui, T., Miyawaki, S., and Honjo, T. 1994. Oral administration of lipopolysaccharides activates B-1 cells in the peritoneal cavity and lamina propria of the gut and induces autoimmune symptoms in an autoantibody transgenic mouse. J. Exp. Med. 80: 111-121.
169. Nagai, Y., Shimazu, R., Ogata, H., Akashi, S., Sudo, K., Yamasaki, H., Hayashi, S., Iwakura, Y., Kimoto, M., and Miyake, K. 2002. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 99: 1699-1705.
170. Nagai, Y., Kobayashi, T., Motoi, Y., Ishiguro, K., Akashi, S., Saitoh, S., Kusumoto, Y., Kaisho, T., Akira, S., Matsumoto, M., Takatsu, K., and Miyake, K. 2005. The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes. J. Immunol. 174: 7043-7049.
171. Nakamura, M., Burastero, S.E., Notkins, A.L., and Casal, P. 1988. Human monoclonal rheumatoid factor-like antibodies from CD5 (Leu-1)+ B cells are polyreactive. J. Immunol. 140: 4180-4186.
172. Nakano, M., Tanabe, M.J., Hori, H., Kondo, S., and Hisatsune, K. 1977. Immunologic properties of Vibrio cholerae lipopolysaccharides. Microbiol. Immunol. 21: 611-619.
173. Nesper, J., Lauriano, C.M., Klose, K.E., Kapfhammer, D., Kraiss, A., and Reidl, J. 2001. Characterization of Vibrio cholerae O1 El tor galU and galE mutants: influence on lipopolysaccharide structure, colonization, and biofilm formation. Infect. Immun. 69: 435-445.
174. Nguyen, H.P., Seto, N.O., MacKenzie, C.R., Brade, L., Kosma, P., Brade, H., and Evans, S.V. 2003. Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct. Biol. 10: 1019-1025.
175. Niess, J.H., and Reinecker, H.C. 2005. Lamina propria dendritic cells in the physiology and pathology of the gastrointestinal tract. Curr. Opin. Gastroenterol. 21: 687-691.
176. Nilssen, D.E., Friman, V., Theman, K., Bjorkander, J., Kilander, A., Holmgren, J., Hanson, L.A., and Brandtzaeg, P. 1993. B-cell activation in duodenal mucosa after oral cholera vaccination in IgA deficient subjects with or without IgG subclass deficiency. Scand. J. Immunol. 38: 201-208.
177. Odendahl, M., Mei, H., Hoyer, B.F., Jacobi, A.M., Hansen, A., Muehlinghaus, G., Berek, C., Hiepe, F., Manz, R., Radbruch, A., and Dorner, T. 2005. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105: 1614-1621.
178. Ogata, H., Su, I., Miyake, K., Nagai, Y., Akashi, S., Mecklenbrauker, I., Rajewsky, K., Kimoto, M., and Tarakhovsky, A. 2000. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J. Exp. Med. 192: 23-29.
179. Oliver, A.M., Martin, F., Gartland, G.L., Carter, R.H., and Kearney, J.F. 1997. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur. J. Immunol. 27: 2366-2374.
180. Oltz, E.M. 2001. Regulation of antigen receptor gene assembly in lymphocytes. Immunol. Res. 23: 121-133.
181. Padlan, E.A., and Kabat, E.A. 1988. Model-building study of the combining sites of two antibodies to alpha (1-6) dextran. Proc. Natl. Acad. Sci. U.S.A. 85: 6885-6889.
182. Pal, S.C., Deb, B.C., Sen Gupta, P.G., De, S.P., Sircar, B.K., Sen, D., and Sikdar, S.N. 1980. A controlled field trial of an aluminum phosphate-adsorbed cholera vaccine in Calcutta. Bull. World Health Organ. 58: 741-745.
183. Park, S.R., Kim, H.A., Chun, S.K., Park, J.B., and Kim, P.H. 2005. Mechanisms underlying the effects of LPS and activation-induced cytidine deaminase on IgA isotype expression. Mol. Cells 19: 445-451.
184. Peng, S.L. 2005. Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol. 17: 230-236.
185. Przetak, M., Chow, J., Cheng, H., Rose, J., Hawkins, L.D., and Ishizaka, S.T. 2003. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine 21: 961-970.
186. Qadri, F., Mohi, G., Hossain, J., Azim, T., Khan, A.M., Salam, M.A,. Sack, R.B., Albert, M.J., and Svennerholm, A.M. 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin. Diagn. Lab. Immunol. 2: 685-688.
187. Qadri, F., Wenneras, C., Albert, M.J., Hossain, J., Mannoor, K., Begum, Y.A., Mohi, G., Salam, M.A., Sack, R.B., and Svennerholm, A.M. 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun. 65: 3571-3576.
188. Qadri, F., Ahmed, F., Karim, M.M., Wenneras, C., Begum, Y.A., Abdus Salam, M., Albert, M.J., and McGhee, J.R. 1999. Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera. Clin. Diagn. Lab. Immunol. 6: 812-818.
189. Qadri, F., Raqib, R., Ahmed, F., Rahman, T., Wenneras, C., Das, S.K., Alam, N.H., Mathan, M.M., and Svennerholm, A.M. 2002. Increased levels of inflammatory mediators in children and adults infected with Vibrio cholerae O1 and O139. Clin. Diagn. Lab. Immunol. 9: 221-229.
190. Qadri, F., Ryan, E.T., Faruque, A.S., Ahmed, F., Khan, A.I., Islam, M.M., Akramuzzaman, S.M., Sack, D.A., and Calderwood, S.B. 2003. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect. Immun. 71: 4808-4814.
191. Qadri, F., Bhuiyan, T.R., Dutta, K.K., Raqib, R., Alam, M.S., Alam, N.H., Svennerholm, A.M., and Mathan, M.M. 2004. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut 53: 62-69.
192. Qadri, F., Chowdhury, M.I., Faruque, S.M., Salam, M.A., Ahmed, T., Begum, Y.A., Saha, A., Alam, M.S., Zaman, K., Seidlein, L.V., Park, E., Killeen, K.P., Mekalanos, J.J., Clemens, J.D., Sack, D.A., and Peru-15 Study Group. 2005. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis. 192: 573-579.
193. Quirk, M. 2002. Home-grown Vietnamese cholera vaccine "completely safe." Lancet Infect. Dis. 2: 198.
194. Reid, R.R., Prodeus, A.P., Khan, W., Hsu, T., Rosen, F.S., and Carroll, M.C. 1997. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. 159: 970-975.
195. Richie, E.E., Punjabi, N.H., Sidharta, Y.Y., Peetosutan, K.K., Sukandar, M.M., Wasserman, S.S., Lesmana, M.M., Wangsasaputra, F.F., Pandam, S.S., Levine, M.M., O'Hanley, P.P., Cryz, S.J., and Simanjuntak, C.H. 2000. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18: 2399-2410.
196. Rodriguez, M.E., Hellwig, S.M., Hozbor, D.F., Leusen, J., van der Pol, W.L., and van de Winkel, J.G. 2001. Fc receptor-mediated immunity against Bordetella pertussis. J. Immunol. 167: 6545-6551.
197. Ryan, E.T., and Calderwood, S.B. 2000. Cholera vaccines. Clin. Infect. Dis. 31: 561-565.
198. Sack, D.A., Clemens, J.D., Huda, S., Harris, J.R., Khan, M.R., Chakraborty, J., Yunus, M., Gomes, J., Siddique, O., Ahmed, F., et al. 1991. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J. Infect. Dis. 164: 407-411.
199. Sack, D.A., Sack, R.B., Nair, G.B., and Siddique, A.K. 2004. Cholera. Lancet 363: 223-233.
200. Sagaert, X., and De Wolf-Peeters, C. 2003. Classification of B-cells according to their differentiation status, their micro-anatomical localisation and their developmental lineage. Immunol. Lett. 90: 179-186.
201. Saha, D.R., Koley, H., Ghosh, A.N., and Nair, G.B. 1997. Sequential changes in gut mucosa of rabbits infected with Vibrio cholerae O139 Bengal: an ultrastructural study. J. Diarrhoeal. Dis. Res. 15: 59-64.
202. Saha, D., LaRocque, R.C., Khan, A.I., Harris, J.B., Begum, Y.A., Akramuzzaman, S.M., Faruque, A.S., Ryan, E.T., Qadri, F., and Calderwood, S.B. 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis. 189: 2318-2322.
203. Saksena, R., Ma, X., Wade, T.K., Kovac, P., and Wade, W.F. 2005. Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa. Carbohydr. Res. 340: 2256-2269.
204. Sanchez, J.L., Hayashi, K.E., Kruger, H.F., Meza, R., English, C.K., Vidal, W., Svennerholm, A.M., and Taylor, D.N. 1995. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians. Trans. R. Soc. Trop. Med. Hyg. 89: 542-545.
205. Saroso, J.S., Bahrawi, W., Witjaksono, H., Budiarso, R.L., Brotowasisto, Bencic, Z., Dewitt, W.E., and Gomez, C.Z. 1978. A controlled field trial of plain and aluminium hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973-75. Bull. World Health Organ. 56: 619-627.
206. Satchell, K.J. 2003. Activation and suppression of the proinflammatory immune response by Vibrio cholerae toxins. Microbes Infect. 5: 1241-1247.
207. Sengupta, D.K., Sengupta, T.K., and Ghose, A.C. 1992. Major outer membrane proteins of Vibrio cholerae and their role in induction of protective immunity through inhibition of intestinal colonization. Infect. Immun. 60: 4848-4855.
208. Shen, L., Collins, J.E., Schoenborn, M.A., and Maliszewski, C.R. 1994. Lipopolysaccharide and cytokine augmentation of human monocyte IgA receptor expression and function. J. Immunol. 152: 4080-4086.
209. Silva, T.M., Schleupner, M.A., Tacket, C.O., Steiner, T.S., Kaper, J.B., Edelman, R., and Guerrant, R. 1996. New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and Q139 Vibrio cholerae. Infect. Immun. 64: 2362-2364.
210. Simanjuntak, C.H., O'Hanley, P., Punjabi, N.H., Noriega, F., Pazzaglia, G., Dykstra, P., Kay, B., Suharyono, Budiarso, A., Rifai, A.R., et al. 1993. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J. Infect. Dis. 168: 1169-1176.
211. Simell, B., Kilpi, T., and Kayhty, H. 2006. Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children. Clin. Exp. Immunol. 143: 543-549.
212. Sinha, V.B., Jacob, A., Srivastava, R., Kaper, J.B., and Srivastava, B.S. 1993. Identification of the flagellar antigens of Vibrio cholerae El Tor and their role in protection. Vaccine 11: 372-375.
213. Smithson, S.L., Kolibab, K., Shriner, A.K., Srivastava, N., Khuder, S., and Westerink, M.A. 2005. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable light chain repertoire. Infect. Immun. 73: 7477-7484.
214. Sommer, A., and Mosley, W.H. 1973. Ineffectiveness of cholera vaccination as an epidemic control measure. Lancet 1: 1232-1235.
215. Spencer, J., Finn, T., Pulford, K.A., Mason, D.Y., and Isaacson, P.G. 1985. The human gut contains a novel population of B lymphocytes which resemble marginal zone cells. Clin. Exp. Immunol. 62: 607-612.
216. Spencer, J., Perry, M.E., and Dunn-Walters, D.K. 1998. Human marginal-zone B cells. Immunol. Today 19: 421-426.
217. Steele, E.J., Chaicumpa, W., and Rowley, D. 1975. Further evidence for cross-linking as a protective factor in experimental cholera: properties of antibody fragments. J. Infect. Dis. 132: 175-180.
218. Steiniger, B., and Barth, P. 2000. Microanatomy and function of the spleen. Adv. Anat. Embryol. Cell Biol. 151III-IX: 1-101.
219. Steiniger, B., Timphus, E.M., Jacob, R., and Barth, P.J. 2005. CD27+ B cells in human lymphatic organs: re-evaluating the splenic marginal zone. Immunology 116: 429-442.
220. Stroeher, U.H., Karageorgos, L.E., Morona, R., and Manning, P.A. 1992. Serotype conversion in Vibrio cholerae O1. Proc. Natl. Acad. Sci. U.S.A. 89: 2566-2570.
221. Suharyono, Simanjuntak, C., Witham, N., Punjabi, N., Heppner, D.G., Losonsky, G., Totosudirjo, H., Rifai, A.R., Clemens, J., Lim, Y.L., et al. 1992. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340: 689-694.
222. Sun, D.X., Mekalanos, J.J., and Taylor, R.K. 1990. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J. Infect. Dis. 161: 1231-1236.
223. Svennerholm, A.M., Holmgren, J., Hanson, L.A., Lindblad, B.S., Quereshi, F., and Rahimtoola, R.J. 1977. Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand. J. Immunol. 6: 1345-1349.
224. Svennerholm, A.M., Hanson, L.A., Holmgren, J., Lindblad, B.S., Nilsson, B., and Quereshi, F. 1980. Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect. Immun. 30: 427-430.
225. Svennerholm, A.M., Gothefors, L., Sack, D.A., Bardhan, P.K., Holmgren, J. 1984. Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull. World Health Organ. 62: 909-918.
226. Tacket, C.O., Forrest, B., Morona, R., Attridge, S.R., LaBrooy, J., Tall, B.D., Reymann, M., Rowley, D., and Levine, M.M. 1990. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58: 1620-1627.
227. Tacket, C.O., Losonsky, G., Nataro, J.P., Cryz, S.J., Edelman, R., Kaper, J.B., and Levine, M.M. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166: 837-841.
228. Taylor, D.N., Cardenas, V., Perez, J., Puga, R., and Svennerholm, A.M. 1999. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Am. J. Trop. Med. Hyg. 61: 869-873.
229. Taylor, R.K., Kirn, T.J., Bose, N., Stonehouse, E., Tripathi, S.A., Kovac, P., and Wade, W.F. 2004. Progress towards development of a cholera subunit vaccine. Chem. Biodiver. 1: 1036-1057.
230. Taylor, R.K., Kirn, T.J., Meeks, M.D., Wade, T.K., and Wade, W.F. 2004. A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure. Infect. Immun. 72: 6050-6060.
231. Tierens, A., Delabie, J., Michiels, L., Vandenberghe, P., and De Wolf-Peeters, C. 1999. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood 93: 226-234.
232. Timens, W., Boes, A., Rozeboom-Uiterwijk, T., and Poppema, S. 1989. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J. Immunol. 143: 3200-3206.
233. Tough, D.F., and Sprent, J. 2003. Immunologic memory, p. 865-900. In Paul, W.E. (ed), Fundamental immunology, Lippincott Williams and Wilkins, Philadelphia.
234. Trach, D.D., Clemens, J.D., Ke., N.T., Thuy, H.T., Son, N.D., Canh, D.G., Hang, P.V., and Rao, M.R. 1997. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349: 231-235.
235. Trach, D.D., Cam, P.D., Ke, N.T., Rao, M.R., Dinh, D., Hang, P.V., Hung, N.V., Canh, D.G., Thiem, V.D., Naficy, A., Ivanoff, B., Svennerholm, A.M., Holmgren, J., and Clemens, J.D. 2002. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Vietnam. Bull. World Health Organ. 80: 2-8.
236. Uren, T.K., Wijburg, O.L., Simmons, C., Johansen, F.E., Brandtzaeg, P., and Strugnell, R.A. 2005. Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies. J. Immunol. 35: 180-188.
237. Vajdy, M., Singh, M., Ugozzoli, M., Briones, M., Soenawan, E., Cuadra, L., Kazzaz, J., Ruggiero, P., Peppoloni, S., Norelli, F., del Giudice, G., and O'Hagan, D. 2003. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 110: 86-94.
238. Villeneuve, S., Souchon, H., Riottot, M.M., Mazie, J.C., Lei, P., Glaudemans, C.P., Kovac, P., Fournier, J.M., and Alzari, P.M. 2000. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc. Natl. Acad. Sci. U.S.A. 97: 8433-8438.
239. Viret, J.F., Favre, D., Wegmuller, B., Herzog, C., Que, J.U., Cryz, S.J., Jr., and Lang, A.B. 1999. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 67: 3680-3685.
240. Wade, T.K., Saksena, R., Shiloach, J., Kováć, P., and Wade, W.F. 2006. Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A. FEMS Immunol. Med. Microbiol. 48: 237-251.
241. Wang, J., Villeneuve, S., Zhang, J., Lei, P., Miller, C.E., Lafaye, P., Nato, F., Szu, S.C., Karpas, A., Bystricky, S., Robbins, J.B., Kovac, P., Fournier, J.M., and Glaudemans, C.P. 1998. On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba. J. Biol. Chem. 273: 2777-2783.
242. Wasserman, S.S., Losonsky, G.A., Noriega, F., Tacket, C.O., Castaneda, E., and Levine, M.M. 1994. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 12: 1000-1003.
243. Watanabe, H., Gust, I.D., and Holmes, I.H. 1978. Human rotavirus and its antibody: their coexistence in feces of infants. J. Clin. Microbiol. 7: 405-409.
244. Watanabe, Y.W., Verwey, F., Buckian, J.C., Williams, H.R., Jr., Phillips, P.E., and Rocha, S.S., Jr. 1969. Some of the properties of mouse protective antigens derived from Vibrio cholerae. Texas Rep. Biol. Med. 27: 275-298.
245. Weber-Mzell, D., Kotanko, P., Hauer, A.C., Goriup, U., Haas, J., Lanner, N., Erwa, W., Ahmaida, I.A., Haitchi-Petnehazy, S., Stenzel, M., Lanzer, G., and Deutsch, J. 2004. Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur. J. Clin. Invest. 34: 224-228.
246. Weller, S., Braun, M.C., Tan, B.K., Rosenwald, A., Cordier, C., Conley, M.E., Plebani, A., Kumararatne, D.S., Bonnet, D., Tournilhac, O., Tchernia, G., Steiniger, B., Staudt, L.M., Casanova, J.L., Reynaud, C.A., and Weill, J.C. 2004. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104: 3647-3654.
247. Wernet, P., Breu, H., Knop, J., and Rowley, D. 1971. Antibacterial action of specific IgA and transport of IgM, IgA, and IgG from serum into the small intestine. J. Infect. Dis. 124: 223-226.
248. Wolfe, D.N., Kirimanjeswara, G.S., and Harvill, E.T. 2005. Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity. Infect. Immun. 73: 6508-6513.
249. Yadav, M., and Iyngkaran, N. 1979. Low incidence of selective IgA deficiency in normal Malaysians. Med. J. Malaysia 34: 145-148.
250. Yazawa, N., Fujimoto, M., Sato, S., Miyake, K., Asano, N., Nagai, Y., Takeuchi, O., Takeda, K., Okochi, H., Akira, S., Tedder, T.F., and Tamaki, K. 2003. CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood 102: 1374-1380.
251. Yoshida, M., Claypool, S.M., Wagner, J.S., Mizoguchi, E., Mizoguchi, A., Roopenian, D.C., Lencer, W.I., and Blumberg, R.S. 2004. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20: 769-783.
252. Zandvoort, A., Lodewijk, M.E., de Boer, N.K., Dammers, P.M., Kroese, F.G., and Timens, W. 2001. CD27 expression in the human splenic marginal zone: the infant marginal zone is populated by naive B cells. Tissue Antigens 58: 234-242.
253. Zandvoort, A., and Timens, W. 2002. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 130: 4-11.
254. Zarnegar, B., He, J.Q., Oganesyan, G., Hoffmann, A., Baltimore, D., and Cheng, G. 2004. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc. Natl. Acad. Sci. U.S.A. 101: 8108-8113.
255. Zhang, J., Liu, Y.J., MacLennan, I.C., Gray, D., and Lane, P.J. 1988. B cell memory to thymus-independent antigens type 1 and type 2: the role of lipopolysaccharide in B memory induction. Eur. J. Immunol. 18: 1417-1424.
256. Zhou, J., Lottenbach, K.R., Barenkamp, S.J., and Reason, D.C. 2004. Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect. Immun. 72: 3505-3514.
257. Zhou, X., Gao da, Q., Michalski, J., Benitez, J.A., and Kaper, J.B. 2004. Induction of interleukin-8 in T84 cells by Vibrio cholerae. Infect. Immun. 72: 389-397.
258. Zhu, J., Miller, M.B., Vance, R.E., Dziejman, M., Bassler, B.L., and Mekalanos, J.J. 2002. Quorum-sensing regulators control virulence gene expression in Vibrio cholerae. Proc. Natl. Acad. Sci. U.S.A. 99: 3129-3134.